CG Oncology, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 48.61 million compared to USD 35.44 million a year ago. Basic loss per share from continuing operations was USD 15.65 compared to USD 11.71 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
28.2 USD | +9.11% | -16.69% | 0.00% |
01:59pm | Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target | MT |
May. 09 | CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 1.72B | |
+28.95% | 48.16B | |
-0.40% | 41.73B | |
+43.57% | 41.03B | |
-5.31% | 28.77B | |
+10.77% | 25.59B | |
-21.84% | 18.96B | |
+8.48% | 12.92B | |
+27.48% | 12.03B | |
-2.76% | 11.77B |
- Stock Market
- Equities
- CGON Stock
- News CG Oncology, Inc.
- CG Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023